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Background: The purpose of this study was to compare the physical activity and caloric intake trends of lipid-low-
ering drug users with those of non-users among Korean adults with dyslipidemia.
Methods: This study was a repeated cross-sectional study with a nationally representative sample of 2,635 Korean 
adults with dyslipidemia based on the 2010–2013 Korea National Health and Nutrition Examination Survey. Physi-
cal activity was assessed using the International Physical Activity Questionnaire, and caloric intake was estimated 
through 24-hour dietary recall. All statistical analyses were conducted using IBM SPSS ver. 21.0 (IBM Co., Armonk, 
NY, USA). The changes in physical activity and caloric intake were investigated for lipid-lowering drug users and 
non-users using generalized linear models.
Results: The proportion of lipid-lowering drug users in the 2010–2013 survey population increased from 3.5% to 
5.0% (P<0.001). Among adults of dyslipidemia, total of 1,562 participants (56.6%) reported taking lipid-lowering 
drugs, and 1,073 (43.4%) reported not taking lipid-lowering drugs. Drug users were more likely to be older and less 
educated and to have a diagnosis of diabetes, higher body mass index, and lower low density lipoprotein cholester-
ol level. Physical activity trends were tested separately for the lipid-lowering drug users and non-users, and a signif-
icant decrease was found among the drug users during the study period. Physical activity among the drug users in 
2013 was 38% lower (1,357.3±382.7 metabolic equivalent [MET]; P for trend=0.002) than in 2010 (2,201.4±442.6 
MET). In contrast, there was no statistically significant difference between drug users and non-users in the trend of 
caloric intake during the same period.
Conclusion: Physical activity significantly decreased among lipid-lowering drug users between 2010 and 2013, 
which was not observed among non-users. The importance of physical activity may need to be re-emphasized for 
lipid-lowering drug users.
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INTRODUCTION
Dyslipidemia is a major risk factor for cardiovascular disease; total cho-
lesterol, low density lipoprotein cholesterol (LDLC), and triglyceride 
levels are directly proportional to the risk of cardiovascular mortality.1) 
Thus, management of blood cholesterol is important to prevent car-
diovascular disease.
 The American College of Cardiology and the American Heart Asso-
ciation (ACC-AHA) and the National Institute for Health and Care Ex-
cellence guidelines for the treatment of blood cholesterol emphasized 
the importance of dietary changes and regular physical activity as the 
first line of management for dyslipidemia.2-5) In a randomized con-
trolled pilot study, the National Cholesterol Education Program 
(NCEP) step 1 diet program reduced total cholesterol and LDLC levels 
by 5% and 13%, respectively, and the NCEP exercise program was as-
sociated with an increase in high density lipoprotein cholesterol level.6)
 The use of lipid-lowering drugs has rapidly increased in Korea and 
the United States,7,8) and implementing the 2013 guidelines of the 
ACC-AHA for the management of cholesterol would increase the 
number of US adults who would be eligible for statin use from 37.5% to 
48.6%.9) Furthermore, caloric and fat intake in Korean and US adults 
has increased over the past 10 years.7,10) Therefore, it is important to in-
vestigate the effects of dietary modification and physical activity on 
patients with dyslipidemia. In the early 2000s, a cross-sectional study, 
the Study of Exercise and Nutrition in Older Rhode Islanders Project, 
showed that participants who reported taking lipid-lowering drugs 
had better lipid profiles and lower caloric intake than statin non-users, 
but no significant difference in physical activity was reported among 
study subjects.11) A cross-sectional study in Sweden in 2004 investigat-
ed the perception of risk factors for cardiovascular disease among 
adults using statins, and found that statin users were more likely to 
avoid fatty foods and to eat foods with a high fiber content.12) A cross-
sectional study using the data of the National Health and Nutrition Ex-
amination Survey (NHANES) conducted during 1999–2010 compared 
the trend of caloric and fat intake between statin users and non-users 
over time and found a significant increase in the caloric and fat intake 
of statin users.13) To our knowledge, no studies have examined the 
cross-sectional relationship between physical activity and the use of 
lipid-lowering drugs among Korean adults with dyslipidemia. The 
purpose of the present study was to compare physical activity and ca-
loric intake trends of lipid-lowering drug users with those of non-users 
among Korean adults with dyslipidemia.
METHODS
1. Data Sources and Participants
The Korea National Health and Nutrition Examination Survey 
(KNHANES), first conducted in 1998, is a nationally representative 
survey that assesses the health and nutritional status of the Korean 
population. The survey is conducted by the Korea Centers for Disease 
Control and Prevention. It has three different components: a health in-
terview survey, health examination, and nutrition survey. The health 
interview survey is used to collect information regarding housing 
characteristics, socioeconomic status, and physical activity using face-
to-face interviews and self-administered questionnaires. The health 
examination includes body measurements and laboratory tests (blood 
and urine). The nutrition survey is conducted using face-to-face inter-
views and collects information regarding dietary behaviors, dietary 
supplement use, food frequency, and food intake.
 In the fifth and sixth KNHANES (2010–2013), of 33,553 participants, 
30,918 subjects were excluded. Subjects were excluded from this study 
if they were less than 20 years old or pregnant women. Also excluded 
were those without dyslipidemia or those with missing data regarding 
dyslipidemia and lipid-lowering drug use. The final sample size for 
this study was 2,635.
2. Variables and Measurements
Subjects were considered to have dyslipidemia if they reported a diag-
nosis of dyslipidemia by a doctor in the health interview survey. We 
defined lipid-lowering drug users as participants with dyslipidemia 
who had been taking lipid-lowering drugs, and we categorized the 
subjects into two groups: lipid-lowering drug users and non-users.
 Food intake was measured through 24-hour dietary recall in the 
KNHANES. The dietary questionnaire was administered during face-
to-face interviews and included the type, amount, and frequency of 
foods or drinks consumed during the previous day.
 Physical activity was assessed using the Korean version of the Inter-
national Physical Activity Questionnaire (IPAQ).14,15) The IPAQ includes 
questions regarding the duration (minutes per day) and frequency 
(days per week) of vigorous, moderate-intensity, and walking activi-
ties, such as the following question: “During the last 7 days, on how 
many days did you perform vigorous physical activities such as heavy 
lifting, heavier gardening or construction work, chopping wood, aero-
bics, jogging/running, or fast bicycling? How much time did you usu-
ally spend doing vigorous physical activities on one of those days?” 
The number of hours was weighted by the specific metabolic equiva-
lent (MET) score for each activity.
 1) Vigorous MET (min/wk)=8.0×vigorous-intensity activity (min/d)× 
vigorous (d/wk)
 2) Moderate MET (min/wk)=4.0×moderate-intensity activity (min/d)× 
moderate (d/wk)
 3) Walking MET (min/wk)=3.3×walking (min/d)×walking (d/wk)
 4) Total MET (min/wk)=sum of vigorous+moderate+walking MET 
scores14,15)
 We extracted the data for sociodemographic characteristics includ-
ing age, sex, level of education, and marital status. Subjects were clas-
sified into the following age groups: 20 to 39 years, 40 to 59 years, and 
60 years or older. Level of education was classified into less than ele-
mentary school (≤6 years), less than high school graduation (≤12 
years), or high school graduation or more (>12 years).
 Self-reported health status was classified into good, intermediate, or 
bad. We categorized alcohol intake into 2 groups: less than once a 
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month or once or more than once a month. Smoking status was classi-
fied into non-smoker or current smoker. Body mass index (BMI), calcu-
lated as weight in kilograms divided by height in meters squared, was 
categorized into 3 groups: <18.5 kg/m2, 18.5–25 kg/m2, or >25 kg/m2.16)
3. Statistical Analysis
All statistical analyses were performed using IBM SPSS ver. 21.0 (IBM 
Co., Armonk, NY, USA). In order to represent the Korean population, 
stratified random sampling (kstrata), cluster sampling (psu), and sam-
pling weights (wt_itvex) were used. Data analyses were performed to 
account for the complex sample design.
 We analyzed the differences in categorical variables (such as level of 
education, marital status, alcohol intake, and smoking status) using 
chi-square tests and continuous variables (total cholesterol level and 
LDLC level) using t-tests in complex sample analysis. General linear 
models were used to estimate the trends of physical activity and calor-
ic intake among Korean adults with dyslipidemia, after adjusting for 
sex, age group, level of education, marital status, BMI, and diagnosis of 
diabetes. P-values <0.05 were considered statistically significant.
RESULTS
In the 2010–2013 KNHANES, the weighted proportion of adults with 
dyslipidemia increased from 6.1% (2010) to 8.7% (2013, P for 
trend<0.001), and the percentage of lipid-lowering drug users signifi-
cantly increased from 3.5% to 5.0% (P for trend<0.001) (Table 1).
 A total of 2,635 participants reported a diagnosis of dyslipidemia. Of 
this population, 1,562 (Weighted proportion, 56.6%) reported taking 
lipid-lowering drugs, and 1,073 Weighted proportion (43.4%) reported 
not taking lipid-lowering drugs (Table 2).
 There were significant differences between the two groups for the 
different variables we examined with the exception of smoking and 
marital status. The mean age of participants was 58.47±0.31 years; the 
average age of drug users was 61.08±0.36 years, which was significantly 
older than that of non-users (55.06±0.48 years, P<0.001).
 Lipid-lowering drug users were more likely to be older, female, and 
less educated, and to have a diagnosis of diabetes, higher BMI, and 
lower LDLC level. The BMI of drug users was 25.26±0.13 kg/m2, which 
was higher than that of non-users (24.84±0.12 kg/m2, P=0.024). Drug 
users had significantly lower levels of total cholesterol and LDLC than 
non-users (P<0.001).
 In Table 3 and Figure 1, adjusted for sex, age group, level of educa-
tion, marital status, BMI, and diagnosis of diabetes, we examined the 
trends of physical activity and caloric intake separately for lipid-lower-
ing drug users and non-users by year in the 2010–2013 study period.
 The physical activity of drug users was 2,201.4±442.6 MET in 2010, 
1,521±406.6 MET in 2011, 1,480.8±674.6 MET in 2012, and 
1,357.3±382.7 MET in 2013, which was 38% lower than that of 2010. 
Thus, the physical activity of drug users significantly decreased from 
2010 to 2013 (P for trend=0.002). The physical activity of non-users de-
creased from 2010 (2,090.4±425.0 MET) to 2013 (1,846.1±430.5 MET), 
but this decrease was not statically significant (P for trend=0.50). There 
was no significant trend in caloric intake during 2010–2013 for either 
drug users (P for trend=0.10) or non-users (P for trend=0.97).
DISCUSSION
Among Korean adults with dyslipidemia, physical activity significantly 
decreased for lipid-lowering drug users, which was not observed 
among non-users in the KNHANES 2010–2013 period.
 To our knowledge, there are no other published studies in Korea ex-
amining the trends of physical activity and caloric intake among adults 
with dyslipidemia. In the 1999–2010 NHANES, the caloric and fat in-
take of statin users during the 1999–2004 study period was lower than 
that of statin non-users. However, statin users increased their caloric 
and fat intake over time until it was higher than in statin non-users.13) 
These results correspond with our findings that dietary modifications 
were not observed. In the Rhode Island cross-sectional study during 
the early 2000s, the caloric intake of statin users among adults older 
than 60 was lower than in statin non-users.11) The cross-sectional study 
in Sweden in 2004 showed statin users consumed higher-fat foods 
than statin non-users.12) This appears to corroborate the aforesaid re-
port that caloric intake of statin users was lower than in the statin non-
users in the NHANES during the early 2000s. A cohort study in primary 
care clinics in the US examined patients who received their first pre-
scription for statins in 2005. These researchers found that 76% of the 
participants wanted to reduce dietary fat intake; however, no signifi-
cant change in caloric and fat intake was reported during the 6-month 
observation period.17) This study had the advantage of being a longitu-
dinal cohort study in which causal relationships may be inferred, but 
the 71-participant sample size was too small and the observation peri-
od of 6 months was too short to confirm the behavioral change associ-
Table 1. Weighted proportion of adults with dyslipidemia* and lipid-lowering drug users, 2010–2013 KNHANES
Year
P-value† P for trend‡
2010 2011 2012 2013 Total
Dyslipidemia 6.1 (592)§ 6.4 (687) 6.8 (642) 8.7 (714) 6.9 (2635) <0.001 <0.001
Drug users 3.5 (346) 3.6 (397) 4.3 (399) 5.0 (420) 4.1 (1562) <0.001 <0.001
Values are presented as % (number).
KNHANES, Korea National Health and Nutrition Examination Survey.
*Reported the diagnosis of dyslipidemia, 2010–2013 KNHANES. †Calculated using chi-square tests in complex sample analysis. ‡Calculated using linear-by-linear association 
in complex sample analysis. §Unweighted sample number.
Jin-Young Oh, et al. • Trends of Physical Activity and Caloric Intake in Lipid-Lowering Drug Users108  www.kjfm.or.kr
http://dx.doi.org/10.4082/kjfm.2016.37.2.105
ated with statin use. We examined the trends of physical activity and 
caloric intake through a nationwide cross-sectional study using the 
KNHANES.
 In the guidelines of blood cholesterol management, lifestyle modifi-
cation is a key component of controlling blood cholesterol and pre-
venting cardiovascular disease.2-5) A decrease in physical activity and 
higher BMI among statin users compared to non-users shows that life-
style management among lipid-lowering drug users is not satisfactory. 
There are three possible hypotheses to explain these results. First, the 
improved levels of total cholesterol and LDLC after taking lipid-lower-
ing drugs could weaken patients’ motivation to follow the recom-
mended physical activity program. Second, patients who are unwilling 
to make lifestyle changes may prefer to take lipid-lowering drugs, 
while physically active patients may prefer not to take the drugs. Third, 
recent dyslipidemia guidelines emphasize pharmacological treat-
ment; thus, patient education regarding lifestyle modifications could 
be weak.13)
 This study had several limitations. Physical activity and caloric in-
take data were obtained through the self-report questionnaires used in 
the KNHANES; thus, there is a risk of self-report bias. In addition, el-
derly patients may have difficulty remembering their physical activities 
and food intake. However, the reliability and validity of the IPAQ were 
proven in 14 centers from 12 countries.14,15) The second limitation is 
that the questionnaire used in the KNHANES investigated only wheth-
er patients were taking any lipid-lowering drugs, not the specific drug 
ingredients. Third, this study is a repeated cross-sectional study rather 
than a cohort study; thus, the participants differed during each study 
period.13) Even though we cannot infer that the physical activity of in-
dividual study participants decreased over time, the nationally repre-
sentative surveillance data of the KNHANES was a strength of this 
study.
 This study found a statistically significant decrease in the physical 
Table 2. Characteristics of lipid-lowering drug users and non-users among Korean adults with dyslipidemia
Characteristic Drug non-users Drug users Total P-value*
Unweighted sample (no.) 1,073 1,562 2,635 NA
Weighted proportion (%) 43.4 56.6 100 NA
Sex
    Male 47.8 39.4 43.0 0.001
    Female 52.2 60.6 57.0
Age (y) 55.06±0.48 61.08±0.36 58.47±0.31 <0.001
    20–39 10.6 3.3 6.5
    40–59 53.9 40.4 46.3
    ≥60 35.5 56.3 47.3
Level of education (y)
    ≤6 27.2 43.0 36.1 <0.001
    ≤12 49.5 42.3 45.4
    >12 23.3 14.8 18.5
Marital status
    Single 4.5 2.6 3.4 0.074
    Married 95.5 97.4 96.6
Self-reported health status
    Good 21.1 13.6 16.8 <0.001
    Intermediate 50.9 47.6 49.0
    Bad 28.0 38.8 34.1
Hypertension diagnosis 38.0 68.5 55.2 <0.001
Diabetes diagnosis 17.2 32.9 26.1 <0.001
Alcohol intake (%)
    <Once a month 45.6 57.8 52.5 <0.001
    ≥Once a month 54.4 42.2 47.5
Smoking status (%)
    Non-smoker 79.1 83.0 81.3 0.077
    Current smoker 20.9 17.0 18.7
Body mass index† (kg/m2) 24.84±0.12 25.26±0.13 25.08±0.9 0.024
    <18.5 0.8 1.1 1.0
    18.5–25.0 55.8 49.8 52.4
    >25.0 43.3 49.1 46.6
Total cholesterol level (mg/dL) 220.2±1.7 174.6±1.2 194.9±1.2 <0.001
Low density lipoprotein cholesterol level (mg/dL) 134.4±2.7 99.1±1.8 117.0±1.9 <0.001
Values are presented as % or mean±standard deviation.
NA, not applicable.
*Calculated using chi-square tests for categorical variables and t-tests for continuous variables in complex sample analysis. †Calculated as weight in kilograms divided by 
height in meters squared.
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activity of Korean patients who reported taking lipid-lowering drugs, 
which was not observed among the non-users during the 2010–2013 
study period. Based on this result, we suggest that the implementation 
of lifestyle modifications is insufficient. Physicians should stress the 
importance of physical activity along with lipid-lowering drugs for lip-
id-lowering drug users. In addition, pharmacological therapy for the 
treatment of cardiovascular and chronic disease is increasing; thus, fu-
ture studies examining the association between taking drugs and life-
style modification may be needed.
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